{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:39:22Z","timestamp":1790563162534,"version":"4.1.0"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11427-025-3016-4","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T02:01:41Z","timestamp":1762567301000},"page":"331-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and application of antibody-drug conjugates in gynecological cancers"],"prefix":"10.1007","volume":"69","author":[{"given":"Ruxi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengke","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"3016_CR1","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1538-7445.AM2020-2890","volume":"80","author":"O Ab","year":"2020","unstructured":"Ab, O., Bartle, L.M., Lanieri, L., Ponte, J.F., Qiu, Q., Sikka, S., Costoplus, J.A., Deats, W., Yoder, N.C., Widdison, W.C., et al. (2020). Abstract 2890: IMGN151\u2014a next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression. Cancer Res 80, 2890.","journal-title":"Cancer Res"},{"key":"3016_CR2","doi-asserted-by":"publisher","first-page":"6369","DOI":"10.1007\/s00210-024-03764-7","volume":"398","author":"MS Abdelhamid","year":"2025","unstructured":"Abdelhamid, M.S., Wadan, A.H.S., Saad, H.A., El-Dakroury, W.A., Hageen, A.W., Mohammed, D.H., Mourad, S., Mohammed, O.A., Abdel-Reheim, M.A., and Doghish, A.S. (2025). Nanoparticle innovations in targeted cancer therapy: advancements in antibody-drug conjugates. Naunyn Schmiedebergs Arch Pharmacol 398, 6369\u20136389.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3016_CR3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","volume":"21","author":"NR Abu-Rustum","year":"2023","unstructured":"Abu-Rustum, N.R., Yashar, C.M., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S.M., Chino, J., Chon, H.S., Crispens, M.A., et al. (2023). NCCN Guidelines\u00ae Insights: cervical cancer, version 1.2024. J Natl Compr Cancer Netw 21, 1224\u20131233.","journal-title":"J Natl Compr Cancer Netw"},{"key":"3016_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/14728222.2018.1498845","volume":"22","author":"A Aithal","year":"2018","unstructured":"Aithal, A., Rauth, S., Kshirsagar, P., Shah, A., Lakshmanan, I., Junker, W.M., Jain, M., Ponnusamy, M.P., and Batra, S.K. (2018). MUC16 as a novel target for cancer therapy. Expert Opin Ther Targets 22, 675\u2013686.","journal-title":"Expert Opin Ther Targets"},{"key":"3016_CR5","doi-asserted-by":"publisher","first-page":"101709","DOI":"10.1016\/j.gore.2025.101709","volume":"58","author":"DJM Ang","year":"2025","unstructured":"Ang, D.J.M., Bok, K.X., Wong, S.L., Li, Y., Wong, A., Yeo, Y.C., Wang, J., Aggarwal, I. M., and Chan, J.J. (2025). Second-line antibody-drug conjugates for the treatment of metastatic human papillomavirus-independent gastric-type adenocarcinoma of cervix: the Singapore experience. Gynecol Oncol Rep 58, 101709.","journal-title":"Gynecol Oncol Rep"},{"key":"3016_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ygyno.2013.03.002","volume":"129","author":"DK Armstrong","year":"2013","unstructured":"Armstrong, D.K., White, A.J., Weil, S.C., Phillips, M., and Coleman, R.L. (2013). Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 129, 452\u2013458.","journal-title":"Gynecol Oncol"},{"key":"3016_CR7","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1039\/D2CS00446A","volume":"51","author":"N Ashman","year":"2022","unstructured":"Ashman, N., Bargh, J.D., and Spring, D.R. (2022). Non-internalising antibody-drug conjugates. Chem Soc Rev 51, 9182\u20139202.","journal-title":"Chem Soc Rev"},{"key":"3016_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","volume":"17","author":"YG Assaraf","year":"2014","unstructured":"Assaraf, Y.G., Leamon, C.P., and Reddy, J.A. (2014). The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat 17, 89\u201395.","journal-title":"Drug Resist Updat"},{"key":"3016_CR9","doi-asserted-by":"publisher","first-page":"102489","DOI":"10.1016\/j.ctrv.2022.102489","volume":"112","author":"S Banerjee","year":"2023","unstructured":"Banerjee, S., Drapkin, R., Richardson, D.L., and Birrer, M. (2023). Targeting NaPi2b in ovarian cancer. Cancer Treat Rev 112, 102489.","journal-title":"Cancer Treat Rev"},{"key":"3016_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/annonc\/mdy023","volume":"29","author":"S Banerjee","year":"2018","unstructured":"Banerjee, S., Oza, A.M., Birrer, M.J., Hamilton, E.P., Hasan, J., Leary, A., Moore, K.N., Mackowiak-Matejczyk, B., Pikiel, J., Ray-Coquard, I., et al. (2018). Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol 29, 917\u2013923.","journal-title":"Ann Oncol"},{"key":"3016_CR11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia, A., Messersmith, W.A., Kio, E.A., Berlin, J.D., Vahdat, L., Masters, G.A., Moroose, R., Santin, A.D., Kalinsky, K., Picozzi, V., et al. (2021). Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol 32, 746\u2013756.","journal-title":"Ann Oncol"},{"key":"3016_CR12","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh, J.D., Isidro-Llobet, A., Parker, J.S., and Spring, D.R. (2019). Cleavable linkers in antibody-drug conjugates. Chem Soc Rev 48, 4361\u20134374.","journal-title":"Chem Soc Rev"},{"key":"3016_CR13","doi-asserted-by":"publisher","first-page":"e0131177","DOI":"10.1371\/journal.pone.0131177","volume":"10","author":"RR Beerli","year":"2015","unstructured":"Beerli, R.R., Hell, T., Merkel, A.S., Grawunder, U., and Hagemeyer, C.E. (2015). Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS One 10, e0131177.","journal-title":"PLoS One"},{"key":"3016_CR14","doi-asserted-by":"publisher","first-page":"115534","DOI":"10.1016\/j.taap.2021.115534","volume":"421","author":"RL Best","year":"2021","unstructured":"Best, R.L., LaPointe, N.E., Azarenko, O., Miller, H., Genualdi, C., Chih, S., Shen, B.Q., Jordan, M.A., Wilson, L., Feinstein, S.C., et al. (2021). Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol Appl Pharmacol 421, 115534.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3016_CR15","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1016\/j.celrep.2020.02.090","volume":"30","author":"Y Bi","year":"2020","unstructured":"Bi, Y., Tu, Z., Zhang, Y., Yang, P., Guo, M., Zhu, X., Zhao, C., Zhou, J., Wang, H., Wang, Y., et al. (2020). Identification of ALPPL2 as a naive pluripotent state-specific surface protein essential for human naive pluripotency regulation. Cell Rep 30, 3917\u20133931.e5.","journal-title":"Cell Rep"},{"key":"3016_CR16","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/2159-8290.CD-16-1414","volume":"7","author":"CU Bialucha","year":"2017","unstructured":"Bialucha, C.U., Collins, S.D., Li, X., Saxena, P., Zhang, X., D\u00fcrr, C., Lafont, B., Prieur, P., Shim, Y., Mosher, R., et al. (2017). Discovery and optimization of HKT288, a cadherin-6-targeting ADC for the treatment of ovarian and renal cancers. Cancer Discov 7, 1030\u20131045.","journal-title":"Cancer Discov"},{"key":"3016_CR17","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1158\/1535-7163.MCT-16-0163","volume":"15","author":"J Black","year":"2016","unstructured":"Black, J., Menderes, G., Bellone, S., Schwab, C.L., Bonazzoli, E., Ferrari, F., Predolini, F., De Haydu, C., Cocco, E., Buza, N., et al. (2016). SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2\/Neu expression. Mol Cancer Ther 15, 1900\u20131909.","journal-title":"Mol Cancer Ther"},{"key":"3016_CR18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s43018-023-00623-x","volume":"4","author":"S Bobisse","year":"2023","unstructured":"Bobisse, S., Bianchi, V., Tanyi, J.L., Sarivalasis, A., Missiaglia, E., P\u00e9tremand, R., Benedetti, F., Torigian, D.A., Genolet, R., Barras, D., et al. (2023). A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nat Cancer 4, 1410\u20131417.","journal-title":"Nat Cancer"},{"key":"3016_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1535-7163.MCT-20-0183","volume":"20","author":"ND Bodyak","year":"2021","unstructured":"Bodyak, N.D., Mosher, R., Yurkovetskiy, A.V., Yin, M., Bu, C., Conlon, P.R., Demady, D.R., DeVit, M.J., Gumerov, D.R., Gurijala, V.R., et al. (2021). The dolaflexin-based antibody-drug conjugate XMT-1536 targets the solid tumor lineage antigen SLC34A2\/NaPi2b. Mol Cancer Ther 20, 896\u2013905.","journal-title":"Mol Cancer Ther"},{"key":"3016_CR20","doi-asserted-by":"publisher","first-page":"e184790","DOI":"10.1172\/JCI184790","volume":"134","author":"JE Boudreau","year":"2024","unstructured":"Boudreau, J.E. (2024). Immune-molecular interactions in high-grade serous ovarian cancer distinguish long-term survivors. J Clin Invest 134, e184790.","journal-title":"J Clin Invest"},{"key":"3016_CR21","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., and Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74, 229\u2013263.","journal-title":"CA Cancer J Clin"},{"key":"3016_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11427-022-2340-4","volume":"67","author":"J Cai","year":"2024","unstructured":"Cai, J., Xu, X., and Saw, P.E. (2024). Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance. Sci China Life Sci 67, 19\u201340.","journal-title":"Sci China Life Sci"},{"key":"3016_CR23","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI127201","volume":"129","author":"Y Cao","year":"2019","unstructured":"Cao, Y. (2019). Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest 129, 3006\u20133017.","journal-title":"J Clin Invest"},{"key":"3016_CR24","doi-asserted-by":"publisher","first-page":"9107","DOI":"10.7150\/thno.62444","volume":"11","author":"YJ Cao","year":"2021","unstructured":"Cao, Y.J., Yu, C., Wu, K.L., Wang, X., Liu, D., Tian, Z., Zhao, L., Qi, X., Loredo, A., Chung, A., et al. (2021). Synthesis of precision antibody conjugates using proximity-induced chemistry. Theranostics 11, 9107\u20139117.","journal-title":"Theranostics"},{"key":"3016_CR25","doi-asserted-by":"publisher","first-page":"174516","DOI":"10.1016\/j.ejphar.2021.174516","volume":"911","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee, S., Sinha, S., and Kundu, C.N. (2021). Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy. Eur J Pharmacol 911, 174516.","journal-title":"Eur J Pharmacol"},{"key":"3016_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","volume":"72","author":"J Chen","year":"2023","unstructured":"Chen, J., Hu, J., Gu, L., Ji, F., Zhang, F., Zhang, M., Li, J., Chen, Z., Jiang, L., Zhang, Y., et al. (2023a). Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother 72, 409\u2013425.","journal-title":"Cancer Immunol Immunother"},{"key":"3016_CR27","doi-asserted-by":"publisher","first-page":"e2302705","DOI":"10.1002\/advs.202302705","volume":"10","author":"X Chen","year":"2023","unstructured":"Chen, X., Hao, Y., Liu, Y., Zhong, S., You, Y., Ao, K., Chong, T., Luo, X., Yin, M., Ye, M., et al. (2023b). NAT10\/ac4C\/FOXP1 promotes malignant progression and facilitates immunosuppression by reprogramming glycolytic metabolism in cervical cancer. Adv Sci 10, e2302705.","journal-title":"Adv Sci"},{"key":"3016_CR28","doi-asserted-by":"publisher","first-page":"21386","DOI":"10.1038\/s41598-024-71977-0","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Ren, X., Dai, Y., and Wang, Y. (2024). Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system. Sci Rep 14, 21386.","journal-title":"Sci Rep"},{"key":"3016_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Xu, Y., Shao, Z., and Yu, K. (2023c). Resistance to antibody-drug conjugates in breast cancer: Mechanisms and solutions. Cancer Commun 43, 297\u2013337.","journal-title":"Cancer Commun"},{"key":"3016_CR30","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-17-1215","volume":"17","author":"X Cheng","year":"2018","unstructured":"Cheng, X., Li, J., Tanaka, K., Majumder, U., Milinichik, A.Z., Verdi, A.C., Maddage, C. J., Rybinski, K.A., Fernando, S., Fernando, D., et al. (2018). MORAb-202, an antibody-drug conjugate utilizing humanized anti-human FR\u03b1 farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity. Mol Cancer Ther 17, 2665\u20132675.","journal-title":"Mol Cancer Ther"},{"key":"3016_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13048-024-01523-z","volume":"17","author":"X Cheng","year":"2024","unstructured":"Cheng, X., Li, P., Jiang, R., Meng, E., and Wu, H. (2024). ADC: a deadly killer of platinum resistant ovarian cancer. J Ovarian Res 17, 196.","journal-title":"J Ovarian Res"},{"key":"3016_CR32","doi-asserted-by":"publisher","first-page":"52553","DOI":"10.18632\/oncotarget.9651","volume":"7","author":"A Cheung","year":"2016","unstructured":"Cheung, A., Bax, H.J., Josephs, D.H., Ilieva, K.M., Pellizzari, G., Opzoomer, J., Bloomfield, J., Fittall, M., Grigoriadis, A., Figini, M., et al. (2016). Targeting folate receptor alpha for cancer treatment. Oncotarget 7, 52553\u201352574.","journal-title":"Oncotarget"},{"key":"3016_CR33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman, R.L., Lorusso, D., Gennigens, C., Gonz\u00e1lez-Mart\u00edn, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., et al. (2021). Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22, 609\u2013619.","journal-title":"Lancet Oncol"},{"key":"3016_CR34","first-page":"A573","volume":"34","author":"N Concin","year":"2024","unstructured":"Concin, N., Hays, J.L., Fidalgo, A.P., Pothuri, B., Banerjee, S.N., Ghamande, S., Ray-Coquard, I., Germanova, A., Rimel, B.J., Lorusso, D., et al. (2024). #168 UPLIFT (ENGOT-Ov67\/GOG-3048): results from the phase 2 trial of upifitamab rilsodotin (UpRi;XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer (PROC). Int J Gynecol Cancer 34, A573\u2013A574.","journal-title":"Int J Gynecol Cancer"},{"key":"3016_CR35","first-page":"6125","volume":"51","author":"LR Coney","year":"1991","unstructured":"Coney, L.R., Tomassetti, A., Carayannopoulos, L., Frasca, V., Kamen, B.A., Colnaghi, M.I., and Zurawski, V.R. (1991). Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 51, 6125\u20136132.","journal-title":"Cancer Res"},{"key":"3016_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh, L., Sadilkova, L., Viricel, W., and Dumontet, C. (2023). Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol 16, 3.","journal-title":"J Hematol Oncol"},{"key":"3016_CR37","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","volume":"7","author":"P Conte","year":"2022","unstructured":"Conte, P., Ascierto, P.A., Patelli, G., Danesi, R., Vanzulli, A., Sandomenico, F., Tarsia, P., Cattelan, A., Comes, A., De Laurentiis, M., et al. (2022). Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open 7, 100404.","journal-title":"ESMO Open"},{"key":"3016_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","volume":"34","author":"RS Copeland-Halperin","year":"2019","unstructured":"Copeland-Halperin, R.S., Liu, J.E., and Yu, A.F. (2019). Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol 34, 451\u2013458.","journal-title":"Curr Opin Cardiol"},{"key":"3016_CR39","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.3390\/cancers13122898","volume":"13","author":"C Corti","year":"2021","unstructured":"Corti, C., Giugliano, F., Nicol\u00f2, E., Ascione, L., and Curigliano, G. (2021). Antibody-drug conjugates for the treatment of breast cancer. Cancers 13, 2898.","journal-title":"Cancers"},{"key":"3016_CR40","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","volume":"32","author":"M Damelin","year":"2015","unstructured":"Damelin, M., Zhong, W., Myers, J., and Sapra, P. (2015). Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 32, 3494\u20133507.","journal-title":"Pharm Res"},{"key":"3016_CR41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","volume":"20","author":"JS de Bono","year":"2019","unstructured":"de Bono, J.S., Concin, N., Hong, D.S., Thistlethwaite, F.C., Machiels, J.P., Arkenau, H. T., Plummer, R., Jones, R.H., Nielsen, D., Windfeld, K., et al. (2019). Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial. Lancet Oncol 20, 383\u2013393.","journal-title":"Lancet Oncol"},{"key":"3016_CR42","first-page":"e1699","volume":"6","author":"JS de Bono","year":"2023","unstructured":"de Bono, J.S., Harris, J.R., Burm, S.M., Vanderstichele, A., Houtkamp, M.A., Aarass, S., Riisnaes, R., Figueiredo, I., Nava Rodrigues, D., Christova, R., et al. (2023). Systematic study of tissue factor expression in solid tumors. Cancer Rep 6, e1699.","journal-title":"Cancer Rep"},{"key":"3016_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","volume":"150","author":"Z Debebe","year":"2015","unstructured":"Debebe, Z., and Rathmell, W.K. (2015). Ror2 as a therapeutic target in cancer. Pharmacol Ther 150, 143\u2013148.","journal-title":"Pharmacol Ther"},{"key":"3016_CR44","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks, E.D. (2021). Disitamab vedotin: first approval. Drugs 81, 1929\u20131935.","journal-title":"Drugs"},{"key":"3016_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/abt\/tbaa024","volume":"3","author":"MP Deonarain","year":"2020","unstructured":"Deonarain, M.P., and Xue, Q. (2020). Tackling solid tumour therapy with small-format drug conjugates. Antibody Ther 3, 237\u2013245.","journal-title":"Antibody Ther"},{"key":"3016_CR46","doi-asserted-by":"publisher","first-page":"101450","DOI":"10.1016\/j.gore.2024.101450","volume":"54","author":"K Dinkins","year":"2024","unstructured":"Dinkins, K., Barton, W., Wheeler, L., Smith, H.J., Mythreye, K., and Arend, R.C. (2024). Targeted therapy in high grade serous ovarian cancer: a literature review. Gynecol Oncol Rep 54, 101450.","journal-title":"Gynecol Oncol Rep"},{"key":"3016_CR47","doi-asserted-by":"publisher","first-page":"e009710","DOI":"10.1136\/jitc-2024-009710","volume":"12","author":"Y Dong","year":"2024","unstructured":"Dong, Y., Zhang, Z., Luan, S., Zheng, M., Wang, Z., Chen, Y., Chen, X., Tong, A., and Yang, H. (2024). Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. J Immunother Cancer 12, e009710.","journal-title":"J Immunother Cancer"},{"key":"3016_CR48","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1093\/oncolo\/oyae177","volume":"29","author":"GK Dy","year":"2024","unstructured":"Dy, G.K., Farooq, A.V., and Kang, J.J. (2024). Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies. Oncologist 29, e1435\u2013e1451.","journal-title":"Oncologist"},{"key":"3016_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton, J.S., Miller, P.E., Mannis, M.J., and Murphy, C.J. (2015). Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocular Pharmacol Ther 31, 589\u2013604.","journal-title":"J Ocular Pharmacol Ther"},{"key":"3016_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","volume":"159","author":"BK Erickson","year":"2020","unstructured":"Erickson, B.K., Najjar, O., Damast, S., Blakaj, A., Tymon-Rosario, J., Shahi, M., Santin, A., Klein, M., Dolan, M., Cimino-Mathews, A., et al. (2020). Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study. Gynecol Oncol 159, 17\u201322.","journal-title":"Gynecol Oncol"},{"key":"3016_CR51","doi-asserted-by":"publisher","first-page":"1367140","DOI":"10.3389\/fonc.2024.1367140","volume":"14","author":"H Feng","year":"2024","unstructured":"Feng, H., Bi, S., Sun, S., Yang, H., Zhou, H., Mao, J., Li, N., and Yang, F. (2024). Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature. Front Oncol 14, 1367140.","journal-title":"Front Oncol"},{"key":"3016_CR52","doi-asserted-by":"publisher","first-page":"e008037","DOI":"10.1136\/jitc-2023-008037","volume":"12","author":"S Frentzas","year":"2024","unstructured":"Frentzas, S., Austria Mislang, A.R., Lemech, C., Nagrial, A., Underhill, C., Wang, W., Wang, Z.M., Li, B., Xia, Y., and Coward, J.I.G. (2024). Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer 12, e008037.","journal-title":"J Immunother Cancer"},{"key":"3016_CR53","doi-asserted-by":"publisher","first-page":"107778","DOI":"10.1016\/j.isci.2023.107778","volume":"26","author":"Z Fu","year":"2023","unstructured":"Fu, Z., Gao, C., Wu, T., Wang, L., Li, S., Zhang, Y., and Shi, C. (2023a). Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. iScience 26, 107778.","journal-title":"iScience"},{"key":"3016_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z., Li, S., Han, S., Shi, C., and Zhang, Y. (2022). Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy. Sig Transduct Target Ther 7, 93.","journal-title":"Sig Transduct Target Ther"},{"key":"3016_CR55","doi-asserted-by":"publisher","first-page":"101795","DOI":"10.1016\/j.eclinm.2022.101795","volume":"55","author":"Z Fu","year":"2023","unstructured":"Fu, Z., Liu, J., Li, S., Shi, C., and Zhang, Y. (2023b). Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Eclinicalmedicine 55, 101795.","journal-title":"Eclinicalmedicine"},{"key":"3016_CR56","doi-asserted-by":"publisher","first-page":"101302","DOI":"10.1016\/j.preteyeres.2024.101302","volume":"103","author":"EE Gabison","year":"2024","unstructured":"Gabison, E.E., Rousseau, A., Labetoulle, M., Gazzah, A., and Besse, B. (2024). Ocular adverse events associated with antibody-drug conjugates used in cancer: focus on pathophysiology and management strategies. Prog Retin Eye Res 103, 101302.","journal-title":"Prog Retin Eye Res"},{"key":"3016_CR57","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.3390\/ijms25115893","volume":"25","author":"N Galant","year":"2024","unstructured":"Galant, N., Krawczyk, P., Monist, M., Obara, A., Gajek, \u0141., Grenda, A., Nico\u015b, M., Kalinka, E., and Milanowski, J. (2024). Molecular classification of endometrial cancer and its impact on therapy selection. Int J Mol Sci 25, 5893.","journal-title":"Int J Mol Sci"},{"key":"3016_CR58","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","volume":"26","author":"R van Geel","year":"2015","unstructured":"van Geel, R., Wijdeven, M.A., Heesbeen, R., Verkade, J.M.M., Wasiel, A.A., van Berkel, S.S., and van Delft, F.L. (2015). Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody-drug conjugates. Bioconjugate Chem 26, 2233\u20132242.","journal-title":"Bioconjugate Chem"},{"key":"3016_CR59","doi-asserted-by":"publisher","first-page":"100579","DOI":"10.1016\/j.esmoop.2022.100579","volume":"7","author":"C Gennigens","year":"2022","unstructured":"Gennigens, C., Jerusalem, G., Lapaille, L., De Cuypere, M., Streel, S., Kridelka, F., and Ray-Coquard, I. (2022). Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open 7, 100579.","journal-title":"ESMO Open"},{"key":"3016_CR60","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/1078-0432.CCR-18-3965","volume":"26","author":"DE Gerber","year":"2020","unstructured":"Gerber, D.E., Infante, J.R., Gordon, M.S., Goldberg, S.B., Mart\u00edn, M., Felip, E., Martinez Garcia, M., Schiller, J.H., Spigel, D.R., Cordova, J., et al. (2020). Phase Ia study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin DNIB0600A in patients with non-small cell lung cancer and platinum-resistant ovarian cancer. Clin Cancer Res 26, 364\u2013372.","journal-title":"Clin Cancer Res"},{"key":"3016_CR61","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jconrel.2018.12.018","volume":"294","author":"F Giansanti","year":"2019","unstructured":"Giansanti, F., Capone, E., Ponziani, S., Piccolo, E., Gentile, R., Lamolinara, A., Di Campli, A., Sallese, M., Iacobelli, V., Cimini, A., et al. (2019). Secreted Gal-3BP is a novel promising target for non-internalizing antibody-drug conjugates. J Control Release 294, 176\u2013184.","journal-title":"J Control Release"},{"key":"3016_CR62","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-23-1079","volume":"30","author":"SB Gitto","year":"2024","unstructured":"Gitto, S.B., Whicker, M., Davies, G., Kumar, S., Kinneer, K., Xu, H., Lewis, A., Mamidi, S., Medvedev, S., Kim, H., et al. (2024). A B7-H4-targeting antibody-drug conjugate shows antitumor activity in PARPi and platinum-resistant cancers with B7-H4 expression. Clin Cancer Res 30, 1567\u20131581.","journal-title":"Clin Cancer Res"},{"key":"3016_CR63","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano, F., Corti, C., Tarantino, P., Michelini, F., and Curigliano, G. (2022). Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep 24, 809\u2013817.","journal-title":"Curr Oncol Rep"},{"key":"3016_CR64","doi-asserted-by":"publisher","first-page":"e007572","DOI":"10.1136\/jitc-2023-007572","volume":"11","author":"E Gray","year":"2023","unstructured":"Gray, E., Ulrich, M., Epp, A., Younan, P., Sahetya, D., Hensley, K., Allred, S., Huang, L. Y., Hahn, J., Gahnberg, K., et al. (2023). SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. J Immunother Cancer 11, e007572.","journal-title":"J Immunother Cancer"},{"key":"3016_CR65","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/onc.2016.237","volume":"36","author":"M Gugnoni","year":"2017","unstructured":"Gugnoni, M., Sancisi, V., Gandolfi, G., Manzotti, G., Ragazzi, M., Giordano, D., Tamagnini, I., Tigano, M., Frasoldati, A., Piana, S., et al. (2017). Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy. Oncogene 36, 667\u2013677.","journal-title":"Oncogene"},{"key":"3016_CR66","doi-asserted-by":"publisher","first-page":"e2306309","DOI":"10.1002\/advs.202306309","volume":"11","author":"Y Guo","year":"2024","unstructured":"Guo, Y., Shen, Z., Zhao, W., Lu, J., Song, Y., Shen, L., Lu, Y., Wu, M., Shi, Q., Zhuang, W., et al. (2024). Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors. Adv Sci 11, e2306309.","journal-title":"Adv Sci"},{"key":"3016_CR67","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/bjc.2017.422","volume":"118","author":"MK Halle","year":"2018","unstructured":"Halle, M.K., Tangen, I.L., Berg, H.F., Hoivik, E.A., Mauland, K.K., Kusonmano, K., Berg, A., Hurtado, A., Kalland, K.H., \u00d8yan, A.M., et al. (2018). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. Br J Cancer 118, 378\u2013387.","journal-title":"Br J Cancer"},{"key":"3016_CR68","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ygyno.2020.05.038","volume":"158","author":"E Hamilton","year":"2020","unstructured":"Hamilton, E., O\u2019Malley, D.M., O\u2019Cearbhaill, R., Cristea, M., Fleming, G.F., Tariq, B., Fong, A., French, D., Rossi, M., Brickman, D., et al. (2020). Tamrintamab pamozirine (SC-003) in patients with platinum-resistant\/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol 158, 640\u2013645.","journal-title":"Gynecol Oncol"},{"key":"3016_CR69","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2022.40.16_suppl.3002","volume":"40","author":"EP Hamilton","year":"2022","unstructured":"Hamilton, E.P., Jauhari, S., Moore, K.N., Rini, B.I., McLeod, R., Lin, J., Izumi, N., Kundu, M.G., Myobatake, Y., Laadem, A., et al. (2022). Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC). J Clin Oncol 40, 3002.","journal-title":"J Clin Oncol"},{"key":"3016_CR70","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","volume":"34","author":"R Hassan","year":"2016","unstructured":"Hassan, R., Thomas, A., Alewine, C., Le, D.T., Jaffee, E.M., and Pastan, I. (2016). Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol 34, 4171\u20134179.","journal-title":"J Clin Oncol"},{"key":"3016_CR71","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ygyno.2023.01.003","volume":"170","author":"TJ Herzog","year":"2023","unstructured":"Herzog, T.J., Pignata, S., Ghamande, S.A., Rubio, M.J., Fujiwara, K., Vulsteke, C., Armstrong, D.K., Sehouli, J., Coleman, R.L., Gabra, H., et al. (2023). Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Gynecol Oncol 170, 300\u2013308.","journal-title":"Gynecol Oncol"},{"key":"3016_CR72","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1055\/s-0039-1687894","volume":"45","author":"Y Hisada","year":"2019","unstructured":"Hisada, Y., and Mackman, N. (2019). Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost 45, 385\u2013395.","journal-title":"Semin Thromb Hemost"},{"key":"3016_CR73","doi-asserted-by":"publisher","first-page":"e0257976","DOI":"10.1371\/journal.pone.0257976","volume":"16","author":"B Itkin","year":"2021","unstructured":"Itkin, B., Garcia, A., Straminsky, S., Adelchanow, E.D., Pereyra, M., Haab, G.A., Bardach, A., and Pathak, M. (2021). Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis. PLoS One 16, e0257976.","journal-title":"PLoS One"},{"key":"3016_CR74","doi-asserted-by":"publisher","first-page":"101086","DOI":"10.1016\/j.drup.2024.101086","volume":"75","author":"M Jiang","year":"2024","unstructured":"Jiang, M., Li, Q., and Xu, B. (2024). Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement. Drug Resist Updat 75, 101086.","journal-title":"Drug Resist Updat"},{"key":"3016_CR75","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula, J.R., Raab, H., Clark, S., Bhakta, S., Leipold, D.D., Weir, S., Chen, Y., Simpson, M., Tsai, S.P., Dennis, M.S., et al. (2008). Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26, 925\u2013932.","journal-title":"Nat Biotechnol"},{"key":"3016_CR76","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1200\/JCO.2009.22.6324","volume":"27","author":"RS Kasthuri","year":"2009","unstructured":"Kasthuri, R.S., Taubman, M.B., and Mackman, N. (2009). Role of tissue factor in cancer. J Clin Oncol 27, 4834\u20134838.","journal-title":"J Clin Oncol"},{"key":"3016_CR77","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","volume":"165","author":"SK Kim","year":"2022","unstructured":"Kim, S.K., Ursell, P., Coleman, R.L., Monk, B.J., and Vergote, I. (2022). Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol 165, 385\u2013392.","journal-title":"Gynecol Oncol"},{"key":"3016_CR78","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-22-2630","volume":"29","author":"K Kinneer","year":"2023","unstructured":"Kinneer, K., Wortmann, P., Cooper, Z.A., Dickinson, N.J., Masterson, L., Cailleau, T., Hutchinson, I., Vijayakrishnan, B., McFarlane, M., Ball, K., et al. (2023). Design and preclinical evaluation of a novel B7-H4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305. Clin Cancer Res 29, 1086\u20131101.","journal-title":"Clin Cancer Res"},{"key":"3016_CR79","first-page":"1048","volume":"44","author":"TL Klug","year":"1984","unstructured":"Klug, T.L., Bast, R.C., Niloff, J.M., Knapp, R.C., and Zurawski, V.R. (1984). Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 44, 1048\u20131053.","journal-title":"Cancer Res"},{"key":"3016_CR80","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","volume":"5","author":"M K\u00f6bel","year":"2008","unstructured":"K\u00f6bel, M., Kalloger, S.E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N.J., Ionescu, D.N., Rajput, A., et al. (2008). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5, e232.","journal-title":"PLoS Med"},{"key":"3016_CR81","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos, P.A., and Matulonis, U.A. (2023). Clinical and translational advances in ovarian cancer therapy. Nat Cancer 4, 1239\u20131257.","journal-title":"Nat Cancer"},{"key":"3016_CR82","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","volume":"255","author":"YV Kovtun","year":"2007","unstructured":"Kovtun, Y.V., and Goldmacher, V.S. (2007). Cell killing by antibody-drug conjugates. Cancer Lett 255, 232\u2013240.","journal-title":"Cancer Lett"},{"key":"3016_CR83","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41568-020-00322-0","volume":"21","author":"S Kumagai","year":"2021","unstructured":"Kumagai, S., Koyama, S., and Nishikawa, H. (2021). Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer 21, 181\u2013197.","journal-title":"Nat Rev Cancer"},{"key":"3016_CR84","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki, L., and Guntupalli, S.R. (2020). Treatment of epithelial ovarian cancer. BMJ 371, m3773.","journal-title":"BMJ"},{"key":"3016_CR85","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","volume":"27","author":"ME Lacouture","year":"2022","unstructured":"Lacouture, M.E., Patel, A.B., Rosenberg, J.E., and O\u2019Donnell, P.H. (2022). Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist 27, e223\u2013e232.","journal-title":"Oncologist"},{"key":"3016_CR86","doi-asserted-by":"publisher","first-page":"TPS3159","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3159","volume":"40","author":"NJ Lakhani","year":"2022","unstructured":"Lakhani, N.J., Friedman, C.F., Perez, C.A., Wehr, A., McGoldrick, S.M., and LoRusso, P. (2022). Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody-drug conjugate directed to ALPP\/ALPPL2 in advanced solid tumors (SGNALPV001, trial in progress). J Clin Oncol 40, TPS3159.","journal-title":"J Clin Oncol"},{"key":"3016_CR87","doi-asserted-by":"publisher","first-page":"S579","DOI":"10.1016\/j.annonc.2024.08.826","volume":"35","author":"D Lee","year":"2024","unstructured":"Lee, D., Kim, Y.N., Park, J., Lee, Y.J., Kim, S., Kim, S.W., and Lee, J.Y. (2024). 765P HER2 expression in ovarian cancer: its relationship with HRD status, and other biomarkers. Ann Oncol 35, S579.","journal-title":"Ann Oncol"},{"key":"3016_CR88","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3390\/ph14101053","volume":"14","author":"DH Lee","year":"2021","unstructured":"Lee, D.H., Choi, S., Park, Y., and Jin, H. (2021). Mucin1 and Mucin16: therapeutic targets for cancer therapy. Pharmaceuticals 14, 1053.","journal-title":"Pharmaceuticals"},{"key":"3016_CR89","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1039\/C5SC02666K","volume":"7","author":"MTW Lee","year":"2015","unstructured":"Lee, M.T.W., Maruani, A., Baker, J.R., Caddick, S., and Chudasama, V. (2015). Next-generation disulfide stapling: reduction and functional re-bridging all in one. Chem Sci 7, 799\u2013802.","journal-title":"Chem Sci"},{"key":"3016_CR90","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12885-017-3289-2","volume":"17","author":"K Levan","year":"2017","unstructured":"Levan, K., Mehryar, M., Mateoiu, C., Albertsson, P., B\u00e4ck, T., and Sundfeldt, K. (2017). Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer 17, 303.","journal-title":"BMC Cancer"},{"key":"3016_CR91","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips, G.D., Li, G., Dugger, D.L., Crocker, L.M., Parsons, K.L., Mai, E., Bl\u00e4ttler, W.A., Lambert, J.M., Chari, R.V.J., Lutz, R.J., et al. (2008). Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68, 9280\u20139290.","journal-title":"Cancer Res"},{"key":"3016_CR92","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1200\/JCO.2022.40.16_suppl.5514","volume":"40","author":"S Lheureux","year":"2022","unstructured":"Lheureux, S., Alqaisi, H., Cohn, D.E., Chern, J.Y., Duska, L.R., Jewell, A., Corr, B., Winer, I.S., Girda, E., Crispens, M.A., et al. (2022). A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150. J Clin Oncol 40, 5514.","journal-title":"J Clin Oncol"},{"key":"3016_CR93","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","volume":"25","author":"BT Li","year":"2024","unstructured":"Li, B.T., Meric-Bernstam, F., Bardia, A., Naito, Y., Siena, S., Aftimos, P., Anderson, I., Curigliano, G., de Miguel, M., Kalra, M., et al. (2024). Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol 25, 707\u2013719.","journal-title":"Lancet Oncol"},{"key":"3016_CR94","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ccell.2019.05.010","volume":"35","author":"JY Li","year":"2019","unstructured":"Li, J.Y., Perry, S.R., Muniz-Medina, V., Wang, X., Wetzel, L.K., Rebelatto, M.C., Masson Hinrichs, M.J., Bezabeh, B.Z., Fleming, R.L., Dimasi, N., et al. (2019). A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 35, 948\u2013949.","journal-title":"Cancer Cell"},{"key":"3016_CR95","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","volume":"18","author":"T Li","year":"2025","unstructured":"Li, T., Zhang, H., Lian, M., He, Q., Lv, M., Zhai, L., Zhou, J., Wu, K., and Yi, M. (2025). Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021. J Hematol Oncol 18, 5.","journal-title":"J Hematol Oncol"},{"key":"3016_CR96","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","volume":"22","author":"X Li","year":"2023","unstructured":"Li, X., Zhou, S., Abrahams, C.L., Krimm, S., Smith, J., Bajjuri, K., Stephenson, H.T., Henningsen, R., Hanson, J., Heibeck, T.H., et al. (2023). Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers. Mol Cancer Ther 22, 155\u2013167.","journal-title":"Mol Cancer Ther"},{"key":"3016_CR97","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4161\/cbt.26106","volume":"14","author":"JM Lin","year":"2013","unstructured":"Lin, J.M., Spidel, J.L., Maddage, C.J., Rybinski, K.A., Kennedy, R.P., Krauthauser, C.L., Park, Y.C., Albone, E.F., Jacob, S., Goserud, M.T., et al. (2013). The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther 14, 1032\u20131038.","journal-title":"Cancer Biol Ther"},{"key":"3016_CR98","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1158\/1078-0432.CCR-14-3383","volume":"21","author":"K Lin","year":"2015","unstructured":"Lin, K., Rubinfeld, B., Zhang, C., Firestein, R., Harstad, E., Roth, L., Tsai, S.P., Schutten, M., Xu, K., Hristopoulos, M., et al. (2015). Preclinical development of an anti-NaPi2b (SLC34A2) antibody-drug conjugate as a therapeutic for non-small cell lung and ovarian cancers. Clin Cancer Res 21, 5139\u20135150.","journal-title":"Clin Cancer Res"},{"key":"3016_CR99","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/PAS.0000000000002342","volume":"49","author":"LH Lin","year":"2025","unstructured":"Lin, L.H., Kaur, H., Kolin, D.L., Nucci, M.R., and Parra-Herran, C. (2025). Claudin-18 and mutation surrogate immunohistochemistry in gastric-type endocervical lesions and their differential diagnoses. Am J Surg Pathol 49, 206\u2013216.","journal-title":"Am J Surg Pathol"},{"key":"3016_CR100","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ygyno.2021.09.023","volume":"163","author":"J Liu","year":"2021","unstructured":"Liu, J., Burris, H., Wang, J.S., Barroilhet, L., Gutierrez, M., Wang, Y., Vaze, A., Commerford, R., Royer-Joo, S., Choeurng, V., et al. (2021). An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol 163, 473\u2013480.","journal-title":"Gynecol Oncol"},{"key":"3016_CR101","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdw401","volume":"27","author":"JF Liu","year":"2016","unstructured":"Liu, J.F., Moore, K.N., Birrer, M.J., Berlin, S., Matulonis, U.A., Infante, J.R., Wolpin, B., Poon, K.A., Firestein, R., Xu, J., et al. (2016). Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol 27, 2124\u20132130.","journal-title":"Ann Oncol"},{"key":"3016_CR102","doi-asserted-by":"publisher","first-page":"36652","DOI":"10.18632\/oncotarget.26413","volume":"9","author":"S Lopez","year":"2018","unstructured":"Lopez, S., Zeybek, B., and Santin, A.D. (2018). Targeting Her2\/neu in uterine serous carcinoma: a paradigm shift in management. Oncotarget 9, 36652\u201336653.","journal-title":"Oncotarget"},{"key":"3016_CR103","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1007\/s11427-022-2288-4","volume":"66","author":"Y Luo","year":"2023","unstructured":"Luo, Y., He, M., Yang, J., Zhang, F., Chen, J., Wen, X., Fan, J., Fan, X., Chai, P., and Jia, R. (2023). A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting m6A-dependent activation of multiple oncogenes. Sci China Life Sci 66, 2138\u20132151.","journal-title":"Sci China Life Sci"},{"key":"3016_CR104","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma, W., Xue, R., Zhu, Z., Farrukh, H., Song, W., Li, T., Zheng, L., and Pan, C. (2023). Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol 12, 10.","journal-title":"Exp Hematol Oncol"},{"key":"3016_CR105","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma, Y., Huang, Y., Zhao, Y., Zhao, S., Xue, J., Yang, Y., Fang, W., Guo, Y., Han, Y., Yang, K., et al. (2024). BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol 25, 901\u2013911.","journal-title":"Lancet Oncol"},{"key":"3016_CR106","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1158\/0008-5472.CAN-05-3434","volume":"66","author":"P Macor","year":"2006","unstructured":"Macor, P., Mezzanzanica, D., Cossetti, C., Alberti, P., Figini, M., Canevari, S., and Tedesco, F. (2006). Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res 66, 3876\u20133883.","journal-title":"Cancer Res"},{"key":"3016_CR107","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah, P.K., Ciurlionis, R., Durbin, K.R., Yeager, R.L., Philip, B.K., Bawa, B., Mantena, S.R., Enright, B.P., Liguori, M.J., and Van Vleet, T.R. (2019). Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther 200, 110\u2013125.","journal-title":"Pharmacol Ther"},{"key":"3016_CR108","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters, J.C., Nickens, D.J., Xuan, D., Shazer, R.L., and Amantea, M. (2018). Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs 36, 121\u2013135.","journal-title":"Invest New Drugs"},{"key":"3016_CR109","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/cncr.10288","volume":"94","author":"MJ Mattes","year":"2002","unstructured":"Mattes, M.J. (2002). Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 94, 1215\u20131223.","journal-title":"Cancer"},{"key":"3016_CR110","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis, U.A., Lorusso, D., Oaknin, A., Pignata, S., Dean, A., Denys, H., Colombo, N., Van Gorp, T., Konner, J.A., Marin, M.R., et al. (2023). Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol 41, 2436\u20132445.","journal-title":"J Clin Oncol"},{"key":"3016_CR111","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-22-2981","volume":"29","author":"MSJ McDermott","year":"2023","unstructured":"McDermott, M.S.J., O\u2019Brien, N.A., Hoffstrom, B., Gong, K.W., Lu, M., Zhang, J., Luo, T., Liang, M., Jia, W., Hong, J.J., et al. (2023). Preclinical efficacy of the antibody-drug conjugate CLDN6-23-ADC for the treatment of CLDN6-positive solid tumors. Clin Cancer Res 29, 2131\u20132143.","journal-title":"Clin Cancer Res"},{"key":"3016_CR112","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ygyno.2024.07.002","volume":"189","author":"B McNamara","year":"2024","unstructured":"McNamara, B., Greenman, M., Bellone, S., Santin, L.A., Demirkiran, C., Mutlu, L., Hartwich, T.M.P., Yang-Hartwich, Y., Ratner, E., Schwartz, P.E., et al. (2024). Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecol Oncol 189, 16\u201323.","journal-title":"Gynecol Oncol"},{"key":"3016_CR113","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.3390\/molecules28217389","volume":"28","author":"B McNamara","year":"2023","unstructured":"McNamara, B., Greenman, M., Pebley, N., Mutlu, L., and Santin, A.D. (2023). Antibody-drug conjugates (ADC) in HER2\/neu-positive gynecologic tumors. Molecules 28, 7389.","journal-title":"Molecules"},{"key":"3016_CR114","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/PGP.0000000000001068","volume":"44","author":"RP Mendoza","year":"2024","unstructured":"Mendoza, R.P., Ramineni, M., Doytcheva, K., Gabutan, E.C., Gupta, R., Miller, C., Choi, D., Vemuri, A., Briese, R., Brannon, L., et al. (2024). Molecular and clinicopathologic characterization of HER2-overexpressed squamous cell carcinoma of the cervix. Int J Gynecol Pathol 44, 323\u2013330.","journal-title":"Int J Gynecol Pathol"},{"key":"3016_CR115","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.Y., Banerjee, S., Gonz\u00e1lez-Mart\u00edn, A., Jung, K.H., \u0141ugowska, I., Manso, L., Manzano, A., et al. (2024). Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 42, 47\u201358.","journal-title":"J Clin Oncol"},{"key":"3016_CR116","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ygyno.2007.03.039","volume":"106","author":"T Miyatake","year":"2007","unstructured":"Miyatake, T., Tringler, B., Liu, W., Liu, S.H., Papkoff, J., Enomoto, T., Torkko, K.C., Dehn, D.L., Swisher, A., and Shroyer, K.R. (2007). B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106, 119\u2013127.","journal-title":"Gynecol Oncol"},{"key":"3016_CR117","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S., Saura, C., Yamashita, T., Park, Y.H., Kim, S.B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020). Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382, 610\u2013621.","journal-title":"N Engl J Med"},{"key":"3016_CR118","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore, K.N., Angelergues, A., Konecny, G.E., Garc\u00eda, Y., Banerjee, S., Lorusso, D., Lee, J.Y., Moroney, J.W., Colombo, N., Roszak, A., et al. (2023). Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med 389, 2162\u20132174.","journal-title":"N Engl J Med"},{"key":"3016_CR119","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ygyno.2020.05.039","volume":"158","author":"KN Moore","year":"2020","unstructured":"Moore, K.N., Birrer, M.J., Marsters, J., Wang, Y., Choi, Y.J., Royer-Joo, S., Lemahieu, V., Armstrong, K., Cordova, J., Samineni, D., et al. (2020). Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 158, 631\u2013639.","journal-title":"Gynecol Oncol"},{"key":"3016_CR120","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","volume":"191","author":"KN Moore","year":"2024","unstructured":"Moore, K.N., Lorusso, D., Oaknin, A., Oza, A., Colombo, N., Van Gorp, T., O\u2019Malley, D. M., Banerjee, S., Murphy, C.G., Harter, P., et al. (2024). Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: an integrated safety summary. Gynecol Oncol 191, 249\u2013258.","journal-title":"Gynecol Oncol"},{"key":"3016_CR121","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore, K.N., Oza, A.M., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Konecny, G.E., Banerjee, S., Murphy, C.G., Tanyi, J.L., et al. (2021). Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol 32, 757\u2013765.","journal-title":"Ann Oncol"},{"key":"3016_CR122","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/1535-7163.MCT-23-0126","volume":"22","author":"L Mutlu","year":"2023","unstructured":"Mutlu, L., Manavella, D.D., Bellone, S., McNamara, B., Harold, J.A., Mauricio, D., Siegel, E.R., Buza, N., Hui, P., Hartwich, T.M.P., et al. (2023). In vivo and in vitro efficacy of trastuzumab deruxtecan in uterine serous carcinoma. Mol Cancer Ther 22, 1404\u20131412.","journal-title":"Mol Cancer Ther"},{"key":"3016_CR123","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/08820139.2020.1775643","volume":"50","author":"C Napodano","year":"2021","unstructured":"Napodano, C., Marino, M.P., Stefanile, A., Pocino, K., Scatena, R., Gulli, F., Rapaccini, G.L., Delli Noci, S., Capozio, G., Rigante, D., et al. (2021). Immunological role of IgG subclasses. Immunol Invests 50, 427\u2013444.","journal-title":"Immunol Invests"},{"key":"3016_CR124","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","volume":"13","author":"S Narod","year":"2016","unstructured":"Narod, S. (2016). Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol 13, 255\u2013261.","journal-title":"Nat Rev Clin Oncol"},{"key":"3016_CR125","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1002\/jcp.26435","volume":"233","author":"H Nasiri","year":"2018","unstructured":"Nasiri, H., Valedkarimi, Z., Aghebati-Maleki, L., and Majidi, J. (2018). Antibody-drug conjugates: promising and efficient tools for targeted cancer therapy. J Cell Physiol 233, 6441\u20136457.","journal-title":"J Cell Physiol"},{"key":"3016_CR126","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","volume":"75","author":"BE Nelson","year":"2024","unstructured":"Nelson, B.E., and Meric-Bernstam, F. (2024). Leveraging TROP2 antibody-drug conjugates in solid tumors. Annu Rev Med 75, 31\u201348.","journal-title":"Annu Rev Med"},{"key":"3016_CR127","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen, T.D., Bordeau, B.M., and Balthasar, J.P. (2023). Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers 15, 713.","journal-title":"Cancers"},{"key":"3016_CR128","doi-asserted-by":"publisher","first-page":"e1329","DOI":"10.1002\/ctm2.1329","volume":"13","author":"C Nieto-Jim\u00e9nez","year":"2023","unstructured":"Nieto-Jim\u00e9nez, C., Sanvicente, A., D\u00edaz-Tejeiro, C., Moreno, V., lopez de S\u00e1, A., Calvo, E., Mart\u00ednez-L\u00f3pez, J., P\u00e9rez-Segura, P., and Oca\u00f1a, A. (2023). Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates. Clin Transl Med 13, e1329.","journal-title":"Clin Transl Med"},{"key":"3016_CR129","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.22.02558","volume":"41","author":"T Nishikawa","year":"2023","unstructured":"Nishikawa, T., Hasegawa, K., Matsumoto, K., Mori, M., Hirashima, Y., Takehara, K., Ariyoshi, K., Kato, T., Yagishita, S., Hamada, A., et al. (2023). Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial. J Clin Oncol 41, 2789\u20132799.","journal-title":"J Clin Oncol"},{"key":"3016_CR130","doi-asserted-by":"publisher","first-page":"S547","DOI":"10.1016\/j.annonc.2024.08.776","volume":"35","author":"A Oaknin","year":"2024","unstructured":"Oaknin, A., Ang, J.E., Rha, S.Y., Yonemori, K., Kristeleit, R., Lin, C.C., Satoh, T., Garcia, P.E., Sendur, M.A.N., Rodr\u00edguez, L.M., et al. (2024). 714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study. Ann Oncol 35, S547\u2013S548.","journal-title":"Ann Oncol"},{"key":"3016_CR131","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1200\/JCO.2023.41.16_suppl.5508","volume":"41","author":"A Oaknin","year":"2023","unstructured":"Oaknin, A., Fari\u00f1as-Madrid, L., Garc\u00eda-Duran, C., Martin, L.P., O\u2019Malley, D.M., Schilder, R.J., Uyar, D., Moroney, J.W., Diaz, J.P., Spira, A.I., et al. (2023). Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolR\u03b1) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolR\u03b1 expression in patients with recurrent epithelial ovarian cancer (OC): update of STRO-002-GM1 phase 1 dose expansion cohort. J Clin Oncol 41, 5508.","journal-title":"J Clin Oncol"},{"key":"3016_CR132","doi-asserted-by":"publisher","first-page":"11076","DOI":"10.1073\/pnas.0402970101","volume":"101","author":"RJ Ober","year":"2004","unstructured":"Ober, R.J., Martinez, C., Lai, X., Zhou, J., and Ward, E.S. (2004). Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA 101, 11076\u201311081.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3016_CR133","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016a). DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22, 5097\u20135108.","journal-title":"Clin Cancer Res"},{"key":"3016_CR134","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y., Hagihara, K., Oitate, M., Naito, H., and Agatsuma, T. (2016b). Bystander killing effect ofDS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107, 1039\u20131046.","journal-title":"Cancer Sci"},{"key":"3016_CR135","first-page":"103","volume":"6","author":"D Oostra","year":"2014","unstructured":"Oostra, D., and Macrae, E. (2014). Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer. Breast Cancer 6, 103\u2013113.","journal-title":"Breast Cancer"},{"key":"3016_CR136","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3390\/ijms25052925","volume":"25","author":"C Pampeno","year":"2024","unstructured":"Pampeno, C., Opp, S., Hurtado, A., and Meruelo, D. (2024). Sindbis virus vaccine platform: a promising oncolytic virus-mediated approach for ovarian cancer treatment. Int J Mol Sci 25, 2925.","journal-title":"Int J Mol Sci"},{"key":"3016_CR137","doi-asserted-by":"publisher","first-page":"12118","DOI":"10.1200\/JCO.2024.42.16_suppl.12118","volume":"42","author":"YH Park","year":"2024","unstructured":"Park, Y.H., Cort\u00e9s, J., Modi, S., Hurvitz, S.A., Bianchini, G., Iwata, H., Shitara, K., Siena, S., Goto, Y., Ku, G.Y., et al. (2024). Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies. J Clin Oncol 42, 12118.","journal-title":"J Clin Oncol"},{"key":"3016_CR138","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","volume":"338","author":"N Parker","year":"2005","unstructured":"Parker, N., Turk, M.J., Westrick, E., Lewis, J.D., Low, P.S., and Leamon, C.P. (2005). Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338, 284\u2013293.","journal-title":"Anal Biochem"},{"key":"3016_CR139","doi-asserted-by":"publisher","first-page":"TPS3155","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3155","volume":"40","author":"A Patnaik","year":"2022","unstructured":"Patnaik, A., Lakhani, N.J., Xu, P., Nazarenko, N.N., and Call, J.A. (2022). Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress). J Clin Oncol 40, TPS3155.","journal-title":"J Clin Oncol"},{"key":"3016_CR140","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.12530","volume":"276","author":"JR Podojil","year":"2017","unstructured":"Podojil, J.R., and Miller, S.D. (2017). Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev 276, 40\u201351.","journal-title":"Immunol Rev"},{"key":"3016_CR141","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell, C.A., Modi, S., Iwata, H., Takahashi, S., Smit, E.F., Siena, S., Chang, D.Y., Macpherson, E., Qin, A., Singh, J., et al. (2022). Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 7, 100554.","journal-title":"ESMO Open"},{"key":"3016_CR142","first-page":"741","volume":"45","author":"Professional Committee on Clinical Research of Oncology Drugs","year":"2023","unstructured":"Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, and Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center. (2023). Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition) (in Chinese). Chin J Oncol 45, 741\u2013762.","journal-title":"Chin J Oncol"},{"key":"3016_CR143","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14740338.2023.2251380","volume":"22","author":"F Raheem","year":"2023","unstructured":"Raheem, F., Alsuhebany, N., Hickey Zacholski, E., Paulic, N., Sandler, A., Uk, N., and Moore, D.C. (2023). Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies. Expert Opin Drug Saf 22, 921\u2013928.","journal-title":"Expert Opin Drug Saf"},{"key":"3016_CR144","doi-asserted-by":"publisher","first-page":"TPS5607","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5607","volume":"39","author":"DL Richardson","year":"2021","unstructured":"Richardson, D.L., Hamilton, E.P., Oaknin, A., Randall, L.M., Banerjee, S.N., Taylor, S. K., Mileshkin, L.R., Coleman, R.L., Monk, B.J., Mirza, M.R., et al. (2021). Uplift (ENGOT-ov67): a pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer. J Clin Oncol 39, TPS5607.","journal-title":"J Clin Oncol"},{"key":"3016_CR145","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","volume":"5","author":"M Ritchie","year":"2013","unstructured":"Ritchie, M., Tchistiakova, L., and Scott, N. (2013). Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. mAbs 5, 13\u201321.","journal-title":"mAbs"},{"key":"3016_CR146","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.addr.2004.01.010","volume":"56","author":"S Sabharanjak","year":"2004","unstructured":"Sabharanjak, S., and Mayor, S. (2004). Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 56, 1099\u20131109.","journal-title":"Adv Drug Deliv Rev"},{"key":"3016_CR147","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.annonc.2024.09.001","volume":"36","author":"H Sakai","year":"2025","unstructured":"Sakai, H., Tsurutani, J., Ozaki, Y., Ishiguro, H., Nozawa, K., Yamanaka, T., Aogi, K., Matsumoto, K., Iwasa, T., Tokiwa, M., et al. (2025). A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). Ann Oncol 36, 31\u201342.","journal-title":"Ann Oncol"},{"key":"3016_CR148","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.yexcr.2005.01.018","volume":"306","author":"S Salceda","year":"2005","unstructured":"Salceda, S., Tang, T., Kmet, M., Munteanu, A., Ghosh, M., Macina, R., Liu, W., Pilkington, G., and Papkoff, J. (2005). The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 306, 128\u2013141.","journal-title":"Exp Cell Res"},{"key":"3016_CR149","doi-asserted-by":"publisher","first-page":"114408","DOI":"10.1016\/j.biopha.2023.114408","volume":"161","author":"A Samantasinghar","year":"2023","unstructured":"Samantasinghar, A., Sunildutt, N.P., Ahmed, F., Soomro, A.M., Salih, A.R.C., Parihar, P., Memon, F.H., Kim, K.H., Kang, I.S., and Choi, K.H. (2023). A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother 161, 114408.","journal-title":"Biomed Pharmacother"},{"key":"3016_CR150","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1200\/JCO.23.02767","volume":"42","author":"AD Santin","year":"2024","unstructured":"Santin, A.D., Corr, B.R., Spira, A., Willmott, L., Butrynski, J., Tse, K.Y., Patel, J., Mekan, S., Wu, T., Lin, K.W., et al. (2024). Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer. J Clin Oncol 42, 3421\u20133429.","journal-title":"J Clin Oncol"},{"key":"3016_CR151","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","volume":"17","author":"M Scaranti","year":"2020","unstructured":"Scaranti, M., Cojocaru, E., Banerjee, S., and Banerji, U. (2020). Exploiting the folate receptor \u03b1 in oncology. Nat Rev Clin Oncol 17, 349\u2013359.","journal-title":"Nat Rev Clin Oncol"},{"key":"3016_CR152","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1159\/000518549","volume":"44","author":"P Sch\u00f6ffski","year":"2021","unstructured":"Sch\u00f6ffski, P., Concin, N., Suarez, C., Subbiah, V., Ando, Y., Ruan, S., Wagner, J.P., Mansfield, K., Zhu, X., Origuchi, S., et al. (2021). A phase 1 study of a CDH6-targeting antibody-drug conjugate in patients with advanced solid tumors with evaluation of inflammatory and neurological adverse events. Oncol Res Treat 44, 547\u2013556.","journal-title":"Oncol Res Treat"},{"key":"3016_CR153","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jconrel.2022.01.017","volume":"343","author":"N Serna","year":"2022","unstructured":"Serna, N., Pallar\u00e8s, V., Unzueta, U., Garcia-Leon, A., Volt\u00e0-Dur\u00e1n, E., S\u00e1nchez-Chardi, A., Parlad\u00e9, E., Rueda, A., Casanova, I., Falg\u00e0s, A., et al. (2022). Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. J Control Release 343, 277\u2013287.","journal-title":"J Control Release"},{"key":"3016_CR154","doi-asserted-by":"publisher","first-page":"S572","DOI":"10.1016\/j.annonc.2024.08.815","volume":"35","author":"R Shapira-Frommer","year":"2024","unstructured":"Shapira-Frommer, R., Sudo, K., Harano, K., Mileshkin, L., Perets, R., Song, M., Cohen, J., Huang, Y.F., Ambrose, H., Brier, T., et al. (2024). 754P initial results from a first-in-human study of AZD5335, a folate receptor \u03b1 (FR\u03b1)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC). Ann Oncol 35, S572\u2013S573.","journal-title":"Ann Oncol"},{"key":"3016_CR155","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2024.42.16_suppl.3012","volume":"42","author":"L Shen","year":"2024","unstructured":"Shen, L., Zhou, C., Meng, X., Sun, Y., Ji, Y., Yang, H., Ning, F., Han, L., Jiang, O., Sun, M., et al. (2024). Results of a phase 1\/2 study of MHB088C: a novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors. J Clin Oncol 42, 3012.","journal-title":"J Clin Oncol"},{"key":"3016_CR156","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","volume":"14","author":"R Sheyi","year":"2022","unstructured":"Sheyi, R., de la Torre, B.G., and Albericio, F. (2022). Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics 14, 396.","journal-title":"Pharmaceutics"},{"key":"3016_CR157","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.apsb.2021.12.013","volume":"12","author":"W Shi","year":"2022","unstructured":"Shi, W., Li, W., Zhang, J., Li, T., Song, Y., Zeng, Y., Dong, Q., Lin, Z., Gong, L., Fan, S., et al. (2022). One-step synthesis of site-specific antibody-drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates. Acta Pharm Sin 12, 2417\u20132428.","journal-title":"Acta Pharm Sin"},{"key":"3016_CR158","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","volume":"27","author":"T Shimizu","year":"2021","unstructured":"Shimizu, T., Fujiwara, Y., Yonemori, K., Koyama, T., Sato, J., Tamura, K., Shimomura, A., Ikezawa, H., Nomoto, M., Furuuchi, K., et al. (2021). First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-\u03b1-positive advanced solid tumors. Clin Cancer Res 27, 3905\u20133915.","journal-title":"Clin Cancer Res"},{"key":"3016_CR159","doi-asserted-by":"publisher","first-page":"TPS3166","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3166","volume":"42","author":"AI Spira","year":"2024","unstructured":"Spira, A.I., Lee, E.K., O\u2019Cearbhaill, R.E., LoRusso, P., Falchook, G.S., Patel, M.R., Richardson, D.L., Covino, N., Lu, W., Marreddy, P., et al. (2024). A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate, in patients with platinum-refractory\/resistant ovarian cancer and other advanced solid tumors. J Clin Oncol 42, TPS3166.","journal-title":"J Clin Oncol"},{"key":"3016_CR160","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt, K., and Ullrich, A. (2008). Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer 8, 473\u2013480.","journal-title":"Nat Rev Cancer"},{"key":"3016_CR161","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/bioengineering11080830","volume":"11","author":"MA Subhan","year":"2024","unstructured":"Subhan, M.A., and Torchilin, V.P. (2024). Advances in siRNA drug delivery strategies for targeted TNBC therapy. Bioengineering 11, 830.","journal-title":"Bioengineering"},{"key":"3016_CR162","first-page":"856","volume":"8","author":"B Sun","year":"2015","unstructured":"Sun, B., Ye, X., Lin, L., Shen, M., and Jiang, T. (2015). Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer. Int J Clin Exp Pathol 8, 856\u2013861.","journal-title":"Int J Clin Exp Pathol"},{"key":"3016_CR163","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14740338.2023.2277801","volume":"23","author":"C Sun","year":"2024","unstructured":"Sun, C., Yang, X., Tang, L., and Chen, J. (2024). A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system. Expert Opin Drug Saf 23, 1049\u20131060.","journal-title":"Expert Opin Drug Saf"},{"key":"3016_CR164","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-23-0287","volume":"23","author":"H Suzuki","year":"2024","unstructured":"Suzuki, H., Nagase, S., Saito, C., Takatsuka, A., Nagata, M., Honda, K., Kaneda, Y., Nishiya, Y., Honda, T., Ishizaka, T., et al. (2024). Raludotatug deruxtecan, a CDH6-targeting antibody-drug conjugate with a DNA topoisomerase I inhibitor DXd, is efficacious in human ovarian and kidney cancer models. Mol Cancer Ther 23, 257\u2013271.","journal-title":"Mol Cancer Ther"},{"key":"3016_CR165","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","volume":"106","author":"SM Swain","year":"2022","unstructured":"Swain, S.M., Nishino, M., Lancaster, L.H., Li, B.T., Nicholson, A.G., Bartholmai, B.J., Naidoo, J., Schumacher-Wulf, E., Shitara, K., Tsurutani, J., et al. (2022). Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis\u2014focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 106, 102378.","journal-title":"Cancer Treat Rev"},{"key":"3016_CR166","first-page":"165","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino, P., Carmagnani Pestana, R., Corti, C., Modi, S., Bardia, A., Tolaney, S.M., Cortes, J., Soria, J., and Curigliano, G. (2022). Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 72, 165\u2013182.","journal-title":"CA Cancer J Clin"},{"key":"3016_CR167","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","volume":"7","author":"P Tarantino","year":"2021","unstructured":"Tarantino, P., Modi, S., Tolaney, S.M., Cort\u00e9s, J., Hamilton, E.P., Kim, S.B., Toi, M., Andr\u00e8, F., and Curigliano, G. (2021). Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol 7, 1873\u20131881.","journal-title":"JAMA Oncol"},{"key":"3016_CR168","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/1535-7163.MCT-22-0786","volume":"22","author":"D Toader","year":"2023","unstructured":"Toader, D., Fessler, S.P., Collins, S.D., Conlon, P.R., Bollu, R., Catcott, K.C., Chin, C.N., Dirksen, A., Du, B., Duvall, J.R., et al. (2023). Discovery and preclinical characterization of XMT-1660, an optimized B7-H4-targeted antibody-drug conjugate for the treatment of cancer. Mol Cancer Ther 22, 999\u20131012.","journal-title":"Mol Cancer Ther"},{"key":"3016_CR169","first-page":"304","volume":"46","author":"Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group","year":"2024","unstructured":"Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group. (2024). Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition) (in Chinese). Chin J Oncol 46, 304\u2013318.","journal-title":"Chin J Oncol"},{"key":"3016_CR170","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1158\/0008-5472.CAN-12-3266","volume":"73","author":"M Trerotola","year":"2013","unstructured":"Trerotola, M., Jernigan, D.L., Liu, Q., Siddiqui, J., Fatatis, A., and Languino, L.R. (2013). Trop-2 promotes prostate cancer metastasis by modulating \u03b21 integrin functions. Cancer Res 73, 3155\u20133167.","journal-title":"Cancer Res"},{"key":"3016_CR171","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2005.08.060","volume":"100","author":"B Tringler","year":"2006","unstructured":"Tringler, B., Liu, W., Corral, L., Torkko, K.C., Enomoto, T., Davidson, S., Lucia, M.S., Heinz, D.E., Papkoff, J., and Shroyer, K.R. (2006). B7-H4 overexpression in ovarian tumors. Gynecol Oncol 100, 44\u201352.","journal-title":"Gynecol Oncol"},{"key":"3016_CR172","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K., Anami, Y., Ha, S.Y.Y., and Yamazaki, C.M. (2024). Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol 21, 203\u2013223.","journal-title":"Nat Rev Clin Oncol"},{"key":"3016_CR173","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.23.02768","volume":"43","author":"D van Dijk","year":"2025","unstructured":"van Dijk, D., Vermij, L., Le\u00f3n-Castillo, A., Powell, M., Jobsen, J., Leary, A., Bowes, D., Mileshkin, L., Genestie, C., J\u00fcrgenliemk-Schulz, I., et al. (2025). Clinical and molecular characteristics of high-risk, recurrent, or metastatic endometrial cancer that is human epidermal growth factor receptor 2-low. J Clin Oncol 43, 443\u2013452.","journal-title":"J Clin Oncol"},{"key":"3016_CR174","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1200\/JCO.2015.63.2596","volume":"34","author":"I Vergote","year":"2016","unstructured":"Vergote, I., Armstrong, D., Scambia, G., Teneriello, M., Sehouli, J., Schweizer, C., Weil, S.C., Bamias, A., Fujiwara, K., Ochiai, K., et al. (2016). A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol 34, 2271\u20132278.","journal-title":"J Clin Oncol"},{"key":"3016_CR175","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote, I., Gonz\u00e1lez-Mart\u00edn, A., Fujiwara, K., Kalbacher, E., Bagam\u00e9ri, A., Ghamande, S., Lee, J.Y., Banerjee, S., Maluf, F.C., Lorusso, D., et al. (2024). Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med 391, 44\u201355.","journal-title":"N Engl J Med"},{"key":"3016_CR176","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/cancers13010044","volume":"13","author":"L Vermij","year":"2020","unstructured":"Vermij, L., Horeweg, N., Leon-Castillo, A., Rutten, T.A., Mileshkin, L.R., Mackay, H.J., Leary, A., Powell, M.E., Singh, N., Crosbie, E.J., et al. (2020). HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes. Cancers 13, 44.","journal-title":"Cancers"},{"key":"3016_CR177","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11427-023-2554-y","volume":"68","author":"J Wang","year":"2025","unstructured":"Wang, J., Zhou, W., Xu, Y., Duan, J., Zhou, Q., Wang, G., Li, L., Xu, C., Wang, W., Cai, S., et al. (2025). Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: Retrospective analyses of the POPLAR\/OAK and CHOICE-01 trials. Sci China Life Sci 68, 249\u2013262.","journal-title":"Sci China Life Sci"},{"key":"3016_CR178","doi-asserted-by":"publisher","first-page":"100148","DOI":"10.1016\/j.modpat.2023.100148","volume":"36","author":"S Wang","year":"2023","unstructured":"Wang, S., Zhou, X., Niu, S., Chen, L., Zhang, H., Chen, H., and Zhou, F. (2023a). Assessment of HER2 in gastric-type endocervical adenocarcinoma and its prognostic significance. Mod Pathol 36, 100148.","journal-title":"Mod Pathol"},{"key":"3016_CR179","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Gong, J., Wang, A., Wei, J., Peng, Z., Wang, X., Zhou, J., Qi, C., Liu, D., Li, J., et al. (2024). Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. Eclinicalmedicine 68, 102415.","journal-title":"Eclinicalmedicine"},{"key":"3016_CR180","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang, Z., Li, H., Gou, L., Li, W., and Wang, Y. (2023b). Antibody-drug conjugates: recent advances in payloads. Acta Pharm Sin B 13, 4025\u20134059.","journal-title":"Acta Pharm Sin B"},{"key":"3016_CR181","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","volume":"15","author":"CD Weekes","year":"2016","unstructured":"Weekes, C.D., Lamberts, L.E., Borad, M.J., Voortman, J., McWilliams, R.R., Diamond, J. R., de Vries, E.G.E., Verheul, H.M., Lieu, C.H., Kim, G.P., et al. (2016). Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther 15, 439\u2013447.","journal-title":"Mol Cancer Ther"},{"key":"3016_CR182","first-page":"3396","volume":"52","author":"SD Weitman","year":"1992","unstructured":"Weitman, S.D., Lark, R.H., Coney, L.R., Fort, D.W., Frasca, V., Zurawski, V.R., and Kamen, B.A. (1992). Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52, 3396\u20133401.","journal-title":"Cancer Res"},{"key":"3016_CR183","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1158\/1078-0432.CCR-14-1578","volume":"21","author":"Y Wen","year":"2015","unstructured":"Wen, Y., Graybill, W.S., Previs, R.A., Hu, W., Ivan, C., Mangala, L.S., Zand, B., Nick, A.M., Jennings, N.B., Dalton, H.J., et al. (2015). Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21, 448\u2013459.","journal-title":"Clin Cancer Res"},{"key":"3016_CR184","doi-asserted-by":"publisher","first-page":"NT","DOI":"10.1158\/1557-3265.OVCASYMP18-NT-113","volume":"25","author":"WR Wiedemeyer","year":"2019","unstructured":"Wiedemeyer, W.R., Bheddah, S., Saechao, C., French, D., Huntzicker, E., Kempema, A., Gavrilyuk, J., Liu, D., Sisodiya, V., He, A., et al. (2019). Abstract NT-113: SC-003, an antibody-drug conjugate targeting dipeptidase 3, exhibits potent antitumor activity in patient-derived xenograft models of high grade serous ovarian cancer. Clin Cancer Res 25, NT\u2013113.","journal-title":"Clin Cancer Res"},{"key":"3016_CR185","doi-asserted-by":"publisher","first-page":"S622","DOI":"10.1016\/j.annonc.2024.08.929","volume":"35","author":"W Wong","year":"2024","unstructured":"Wong, W., Adkins, D.R., Misleh, J.G., Lorch, J., Grewal, J.S., Russell, J., Cetnar, J., Ho, A.L., Chen, K., Aysola, K., et al. (2024). 868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN). Ann Oncol 35, S622\u2013S623.","journal-title":"Ann Oncol"},{"key":"3016_CR186","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1016\/j.annonc.2023.09.558","volume":"34","author":"J Wu","year":"2023","unstructured":"Wu, J., Zhang, J., Li, H., Wang, X., Zhang, Q.Y., Shi, Y., M. yan, Y., Pan, Y., Shen, A., Chen, Q., et al. (2023). 381O First-in-human\/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors. Ann Oncol 34, S336.","journal-title":"Ann Oncol"},{"key":"3016_CR187","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40164-022-00347-1","volume":"11","author":"M Wu","year":"2022","unstructured":"Wu, M., Huang, W., Yang, N., and Liu, Y. (2022a). Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. Exp Hematol Oncol 11, 93.","journal-title":"Exp Hematol Oncol"},{"key":"3016_CR188","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13048-025-01628-z","volume":"18","author":"Y Wu","year":"2025","unstructured":"Wu, Y., Xia, L., Song, C., Chen, X., and Wu, X. (2025). Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report. J Ovarian Res 18, 43.","journal-title":"J Ovarian Res"},{"key":"3016_CR189","doi-asserted-by":"publisher","first-page":"e2214278119","DOI":"10.1073\/pnas.2214278119","volume":"119","author":"Y Wu","year":"2022","unstructured":"Wu, Y., Fang, Y., Wei, Q., Shi, H., Tan, H., Deng, Y., Zeng, Z., Qiu, J., Chen, C., Sun, L., et al. (2022b). Tumor-targeted delivery of a STING agonist improves cancer immunotherapy. Proc Natl Acad Sci USA 119, e2214278119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3016_CR190","doi-asserted-by":"publisher","first-page":"116709","DOI":"10.1016\/j.ejmech.2024.116709","volume":"276","author":"M Xi","year":"2024","unstructured":"Xi, M., Zhu, J., Zhang, F., Shen, H., Chen, J., Xiao, Z., Huangfu, Y., Wu, C., Sun, H., and Xia, G. (2024). Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads. Eur J Med Chem 276, 116709.","journal-title":"Eur J Med Chem"},{"key":"3016_CR191","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ygyno.2025.03.027","volume":"196","author":"H Xie","year":"2025","unstructured":"Xie, H., Sun, L., Yao, S., Tian, X., Jin, L., Dai, Y., Li, Y., Li, Y., Fang, J., Guo, P., et al. (2025). Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates. Gynecol Oncol 196, 16\u201327.","journal-title":"Gynecol Oncol"},{"key":"3016_CR192","doi-asserted-by":"publisher","first-page":"1339806","DOI":"10.3389\/fonc.2024.1339806","volume":"14","author":"Y Xing","year":"2024","unstructured":"Xing, Y., Cao, Y., Wu, X., Chen, Y., and Wang, Y. (2024). Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level HER-2 expression: a case report. Front Oncol 14, 1339806.","journal-title":"Front Oncol"},{"key":"3016_CR193","doi-asserted-by":"publisher","first-page":"101710","DOI":"10.1016\/j.xcrm.2024.101710","volume":"5","author":"G Xu","year":"2024","unstructured":"Xu, G., Liu, W., Wang, Y., Wei, X., Liu, F., He, Y., Zhang, L., Song, Q., Li, Z., Wang, C., et al. (2024). CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep Med 5, 101710.","journal-title":"Cell Rep Med"},{"key":"3016_CR194","doi-asserted-by":"publisher","first-page":"e14614","DOI":"10.1200\/JCO.2023.41.16_suppl.e14614","volume":"41","author":"M Xu","year":"2023","unstructured":"Xu, M., Chen, R., Xing, P., Kong, Y., Zhao, X., Zhang, J., Cai, S., and Zhang, L. (2023). A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1\/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors. J Clin Oncol 41, e14614.","journal-title":"J Clin Oncol"},{"key":"3016_CR195","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan, T., Zhu, L., and Chen, J. (2023). Current advances and challenges in CAR T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol 12, 14.","journal-title":"Exp Hematol Oncol"},{"key":"3016_CR196","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12943-024-01977-1","volume":"23","author":"S Yang","year":"2024","unstructured":"Yang, S., Hu, C., Chen, X., Tang, Y., Li, J., Yang, H., Yang, Y., Ying, B., Xiao, X., Li, S., et al. (2024). Crosstalk between metabolism and cell death in tumorigenesis. Mol Cancer 23, 71.","journal-title":"Mol Cancer"},{"key":"3016_CR197","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.3802\/jgo.2022.33.e82","volume":"33","author":"S Yazaki","year":"2022","unstructured":"Yazaki, S., Kojima, Y., Yoshida, H., Takamizawa, S., Kitadai, R., Nishikawa, T., Shimoi, T., Sudo, K., Saito, A., Okuma, H.S., et al. (2022). High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer. J Gynecol Oncol 33, e82.","journal-title":"J Gynecol Oncol"},{"key":"3016_CR198","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","volume":"22","author":"M Yi","year":"2023","unstructured":"Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., and Wu, K. (2023). Exploiting innate immunity for cancer immunotherapy. Mol Cancer 22, 187.","journal-title":"Mol Cancer"},{"key":"3016_CR199","doi-asserted-by":"publisher","first-page":"115452","DOI":"10.1016\/j.jpba.2023.115452","volume":"233","author":"F Yin","year":"2023","unstructured":"Yin, F., DeCiantis, C., Pinkas, J., Das, B., Wang, F., Zheng, N., Hahn, D., Amrite, A., Feng, J., Adhikari, D., et al. (2023). Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies. J Pharm Biomed Anal 233, 115452.","journal-title":"J Pharm Biomed Anal"},{"key":"3016_CR200","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"J Yu","year":"2020","unstructured":"Yu, J., Song, Y., and Tian, W. (2020). How to select IgG subclasses in developing antitumor therapeutic antibodies. J Hematol Oncol 13, 45.","journal-title":"J Hematol Oncol"},{"key":"3016_CR201","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1080\/14796694.2024.2407756","volume":"20","author":"Z Zalaquett","year":"2024","unstructured":"Zalaquett, Z., Rita Hachem, M.C., Assi, A., Mohanna, R., Farhat, M., Noujaim, C., and Kourie, H.R. (2024). Cardiac toxicity of HER-2 targeting antibody-drug conjugates: overview and clinical implications. Future Oncol 20, 3151\u20133167.","journal-title":"Future Oncol"},{"key":"3016_CR202","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","volume":"23","author":"X Zang","year":"2010","unstructured":"Zang, X., Sullivan, P.S., Soslow, R.A., Waitz, R., Reuter, V.E., Wilton, A., Thaler, H.T., Arul, M., Slovin, S.F., Wei, J., et al. (2010). Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23, 1104\u20131112.","journal-title":"Mod Pathol"},{"key":"3016_CR203","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1200\/JCO.2024.42.16_suppl.3013","volume":"42","author":"J Zhang","year":"2024","unstructured":"Zhang, J., Liu, R., Gao, S., Yang, H., Chen, J., Yuan, F., Liu, J., Guo, H., Zhang, S., Li, X. Y., et al. (2024). 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: results from a phase 1\/2a study. J Clin Oncol 42, 3013.","journal-title":"J Clin Oncol"},{"key":"3016_CR204","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-023-00431-0","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Zhou, W., Yang, J., Yang, J., and Wang, W. (2023). Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol 12, 70.","journal-title":"Exp Hematol Oncol"},{"key":"3016_CR205","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-024-00493-8","volume":"13","author":"L Zhou","year":"2024","unstructured":"Zhou, L., Lu, Y., Liu, W., Wang, S., Wang, L., Zheng, P., Zi, G., Liu, H., Liu, W., and Wei, S. (2024). Drug conjugates for the treatment of lung cancer: From drug discovery to clinical practice. Exp Hematol Oncol 13, 26.","journal-title":"Exp Hematol Oncol"},{"key":"3016_CR206","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/1535-7163.MCT-22-0743","volume":"22","author":"W Zhou","year":"2023","unstructured":"Zhou, W., Fang, P., Yu, D., Ren, H., You, M., Yin, L., Mei, F., Zhu, H., Wang, Z., Xu, H., et al. (2023). Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers. Mol Cancer Ther 22, 913\u2013925.","journal-title":"Mol Cancer Ther"},{"key":"3016_CR207","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y., Liu, K., Wang, K., and Zhu, H. (2023). Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. Cancer 129, 283\u2013295.","journal-title":"Cancer"},{"key":"3016_CR208","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1007\/s11427-024-2761-y","volume":"68","author":"Y Zhu","year":"2025","unstructured":"Zhu, Y., Zheng, Y., Zhang, Q., Chen, L., Ouyang, Y., Song, Z., Zhao, B., Gu, C., Kong, B., Huang, H., et al. (2025). Multi-omics analysis revealed the addiction to glutamine and susceptibility to de novo lipogenesis of endometrial neoplasm. Sci China Life Sci 68, 2923\u20132933.","journal-title":"Sci China Life Sci"},{"key":"3016_CR209","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/bc400490z","volume":"25","author":"ES Zimmerman","year":"2014","unstructured":"Zimmerman, E.S., Heibeck, T.H., Gill, A., Li, X., Murray, C.J., Madlansacay, M.R., Tran, C., Uter, N.T., Yin, G., Rivers, P.J., et al. (2014). Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjugate Chem 25, 351\u2013361.","journal-title":"Bioconjugate Chem"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3016-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-025-3016-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3016-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:03:27Z","timestamp":1770815007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-025-3016-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":209,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3016"],"URL":"https:\/\/doi.org\/10.1007\/s11427-025-3016-4","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}